Functional Significance of Vitamin D Receptor FokI Polymorphism in Human Breast Cancer Cells by Alimirah, Fatouma et al.
Functional Significance of Vitamin D Receptor FokI
Polymorphism in Human Breast Cancer Cells
Fatouma Alimirah
1,2, Xinjian Peng
1, Genoveva Murillo
1,2, Rajendra G. Mehta
1,2*
1Division of Cancer Biology, IIT Research Institute, Illinois Institute of Technology, Chicago, Illinois, United States of America, 2Department of Biological Chemical and
Physical Sciences, Illinois Institute of Technology, Chicago, Illinois, United States of America
Abstract
Background: The FokI vitamin D receptor (VDR) polymorphism results in different translation initiation sites on VDR. In the
VDRff variant, initiation of translation occurs at the first ATG site, giving rise to a full length VDR protein of 427 amino acids.
Conversely, in the VDRFF variant, translation begins at the second ATG site, resulting in a truncated protein with three less
amino acids. Epidemiological studies have paradoxically implicated this polymorphism with increased breast cancer risk.
1a,25 (OH)2D3, the active metabolite of vitamin D, is known to inhibit cell proliferation, induce apoptosis and potentiate
differentiation in human breast cancer cells. It is well documented that 1a,25 (OH)2D3 downregulates estrogen receptor a
expression and inhibits estrogen mediated signaling in these cells. The functional significance of the VDR FokI
polymorphism in vitamin D action is undefined.
Methods/Findings: To elucidate the functional role of FokI polymorphism in breast cancer, MCF-7-Vector, MCF-7-VDRff and
MCF-7-VDRFF stable cell lines were established from parental MCF-7 cells as single-cell clones. In response to 1a,25 (OH)2D3
treatments, cell growth was inhibited by 60% in VDRFF cells compared to 28% in VDRff cells. The induction of the vitamin D
target gene CYP24A1 mRNA was 1.8 fold higher in VDRFF cells than in VDRff cells. Estrogen receptor-a protein expression
was downregulated by 62% in VDRFF cells compared to 25% in VDRff cells. VDR protein stability was greater in MCF-7-
VDRFF cells in the presence of cycloheximide. PCR array analyses of VDRff and VDRFF cells revealed increased basal
expression levels of pro-inflammatory genes Cyclooxygenase-2, Interleukin-8 and Chemokine (C-C Motif) Ligand 2 in MCF-7-
VDRff cells by 14, 52.7 and 5 fold, respectively.
Conclusions/Significance: These results suggest that a VDRff genotype may play a role in amplifying aggressive breast
cancer, paving the way for understanding why some breast cancer cells respond inefficiently to vitamin D treatment.
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Introduction
The onset and progression of breast cancer is multifactorial and
not fully defined. It is well established that 1a,25(OH)2D3
(1,25D3), the active metabolite of vitamin D, plays a pivotal role
in negatively affecting breast cancer cells by inhibiting cell
proliferation, curtailing invasiveness, inducing apoptosis and
potentiating differentiation [1]. Furthermore, lower circulating
levels of vitamin D in women have been positively linked with
enhanced breast cancer risk and disease mortality [2,3].
Vitamin D action is mediated by the nuclear receptor and
transcription factor Vitamin D receptor (VDR). Upon binding to
1,25D3, VDR heterodimerizes with RXR, another nuclear
receptor, and together they bind to specific vitamin D response
elements (VDREs) in promoter regions of vitamin D target genes,
executing transcriptional effects [1]. Alternatively, in a vitamin D
independent manner, VDR itself has also been shown to dimerize
with RXR and regulate specific target genes [4]. Importantly,
experimental studies on mammary tumors derived from mice
lacking VDR have shown it necessary for vitamin D action as
1,25D3 failed to inhibit cell proliferation and apoptosis in these
cells [5].
Consistent with its essential role in vitamin D mediated effects on
breast cancer, several polymorphisms in the VDR gene have been
identified and their possible significance in breast cancer has been
inconclusively assessed in epidemiological investigations across
multi-ethnic groups [6,7]. One such polymorphism is the FokI
polymorphism restriction site located on exon 2 in the 59 coding
region of the gene [6]. This polymorphism results in different
translation initiation sites on VDR. A thymine (T) to a cytosine (C)
conversion in the first translation initiation codon ATG (methio-
nine) generates long and short variants of VDR. In the VDRff
variant initiation of translation occurs at the first ATG site, giving
rise to a full length VDR protein comprised of 427 amino acids.
Conversely, in the VDRFF variant translation begins at the second
ATG site instead of the first, resulting in a truncated protein with
three less amino acids. This is the only known VDR polymorphism
resulting in two different VDR protein products [6].
The FokI polymorphism, either singly or in combination with
other VDR polymorphisms, has been extensively investigated in
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et al reported that the FokI FF allele together with other VDR
polymorphisms, amplified breast cancer risk in a Caucasian
population in the United Kingdom [8]. On the other hand, two
other studies found that women with the ff genotype were more
susceptible to breast cancer than those with the FF genotype
[9,10], while another study did not observe any correlation
between the FokI polymorphism and increased breast cancer risk
in postmenopausal women [11]. These conflicting conclusions are
often derived due to small sample sizes, compounding variables
and selection biases in patient populations for each study.
However, more recently, two reports with meta-analyses of
multiple studies with large sample sizes provide evidence for a
positive association between the FokI ff genotype and an
augmented predisposition to the disease [12,13]. However, these
reports do not provide any conclusive evidence linking either the
VDRff or VDRFF variant to breast cancer risk or responsiveness
to vitamin D. Therefore, it is necessary to evaluate functional
differences between polymorphic alleles experimentally in breast
cancer cells.
In the present study, we established three cell lines from single
cell clones: Vector control and cells stably overexpressing VDRff
and VDRFF variants in parental MCF-7 cells and determined
their functional significance in breast cancer. This is the first report
documenting a differential response to 1,25D3 in relation to cell
proliferation, transactivation of vitamin D target gene, CYP24A1
and modulation of estrogen receptor signaling among the two
VDR alleles in breast cancer cells. We also report differential basal
expression of pro-inflammatory genes in VDRff and VDRFF
overexpressing breast cancer cells, which may be responsible for
the amplified genetic susceptibility to an aggressive form of the
disease.
Materials and Methods
Cell culture and reagents
The MCF-7(ER+,P R +,VDR+) and the MDA-MB231 (ER-,
PR-, VDR+) human breast cancer cell lines were purchased from
the American Type Culture Collection (Manassas, VA). The cell
lines were maintained in MEM medium (Invitrogen Life
Technologies, Carlsbad, CA) supplemented with 10% Fetal
Bovine Serum, 0.01% non-essential amino acids and antibiotics.
1,25D3 was purchased from Cayman Biochemicals (Ann Arbor,
MI); whereas 17b-estradiol (E2) and tamoxifen were obtained
from Sigma-Aldrich Corp., (St. Louis MO). Cycloheximide was
purchased from A.G. Scientific INC, (San Diego, CA).
Single clonal cell establishment
Parental MCF-7 cells were subjected to serial dilutions in 96
well plates to obtain a single cell-colony per well. Expanded single
colonies were transferred to a 24 well plate and subsequent clones
were further isolated as single cells using clonal cylinders. These
colonies were then transferred to 12 well plates and subsequently
subjected to immunoblotting for basal VDR protein expression.
The clone expressing the lowest basal VDR protein was selected
for stable transfection.
Stable cell line generation and treatment
The above mentioned clone was stably transfected in 60 mm
plates with 5 mg of pcDNA3.1 Vector control, VDRff and VDRFF
expression constructs using Lipofectamine 2000 (Invitrogen) per
the manufacturer’s instructions. The full length pcDNA3.1 human
VDRff was generously provided by Dr. Xiao-Kun Zhang
(Burnham Research Institute, La Jolla, CA). The FF allele
construct was generated from the VDRff plasmid by site directed
mutagenesis by utilizing the QuickChange site directed mutagen-
esis kit (Stratagene, La Jolla, CA). Two complimentary oligonu-
cleotides of 30 nucleotides each were used. These nucleotides
spanned the ATG initiation codon and differed from the template
sequence by an ACG instead of an ATG. The entire VDR coding
sequence of both VDRff and VDRFF was verified by DNA
sequencing. Twenty four hours post-transfection, the cells were
split into 100 mm plates and selected with 800 mg/ml G418 (RPI,
Palos Heights, IL) for one month. Forty eight G418 resistant single
clones were isolated with clonal cylinders and cultured in 24 well
plates and thirteen of these independent clones as well as pooled
clones were successfully established as cell lines designated as
MCF-7-Vector, MCF-7-VDRff and MCF-7-VDRFF. The VDR
protein expression for each of these cell lines was determined by
western blot analysis. The Vector, VDRff and VDRFF clones
were randomly selected and designated as clones 1, 2 and 3 as
outlined in Figure 1C. The numbers above the figure correspond
to the clone number. To circumvent artifactual effects, where
indicated, two to three individual clones were analyzed. All clones
were maintained in medium containing 200 mg/ml G418 and all
experiments were conducted between passages 4 and 15. The
MDA-MB231 cells overexpressing VDRff and VDRFF were
transfected using a similar approach and pooled colonies were
utilized. All cells were visualized at 406 magnification by phase
contrast microscopy (Olympus DP70).
Western blot analysis and co-immunoprecipitation
Total cell lysates were prepared and subjected to western blot
analysis as previously described (14). VDR rat monoclonal (Clone
9A7y.E10.E4) antibody was purchased from Neomarkers (Free-
mont, CA). Antibodies specific for ERa (sc-8005), RXRa (sc-553),
control anti-IgG (sc-2027) and b-Actin (sc-1616) as well as all
secondary antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Immunoprecipitation was performed as
previously described [14].
Cell proliferation analysis
Cell proliferation was assessed by the crystal violet assay and cell
counting as previously described [15]. In experiments assessing
estrogen receptor mediated signaling, cells were incubated with
phenol free MEM medium supplemented with 5% charcoal
stripped serum, 0.01% MEM-non-essential amino acids, 0.01% L-
glutamine and antibiotics (Invitrogen). The cells were treated with
either 1,25D3 (100 nM), 17b-estradiol (10 nM) or tamoxifen
(1 mM) for 4 and 7 days and subjected to the crystal violet assay
and Absorbance was ascertained at 570 nM as previously
described [15]. The cell counting was carried out using the Z1
Coulter Particle Counter (Beckman Coulter, Fullerton, CA).
Reporter assays
The CYP-24 promoter-luciferase reporter plasmid was generat-
ed by isolating genomic DNA via PCR. Approximately 400 base
pairs of the 59 flanking region (2296/+109 relative to the
transcription start site) of CYP24 was used. The genomic DNA
was extracted from MDA-MB435 cells using Advantage2 PCR kit
(Clonetech). The CYP24 was cloned to the kpn/BgI II sites of the
promoterless pGL3 basic vector (Promega, Madison, WI). MDA-
MB231 cells were transiently transfected with 0.3 mg CYP24-luc,
0.3 mg either of VDRff or VDRFF plasmids and 10 ng phRL-TK
internal control per well in 12 well plates using Lipofectamine
2000 (Invitrogen) per the manufacturer’s instructions. Twenty four
hours post-transfection, cells were incubated in the presence or
absence of 100 nM 1,25D3 for twenty four hours and subsequently
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Dual- Luciferase Reproter Assay Kit (Promega, Madison, WI).
The firefly luciferase activity was normalized to Renilla luciferase
activity.
qRT-PCR analysis and PCR Array
Following the experimental treatments, total RNA was isolated
from the cells using TRIzol reagent (Invitrogen) as suggested by
the supplier. cDNA synthesis and qRT-PCR analysis was
conducted as previously described and all samples were normal-
ized to Actin control [16]. The Signal Transduction Pathway
Finder PCR Array of 84 genes (SA, Biosciences, Frederick, MD)
was performed according to the manufacturer’s instructions. For
the PCR array, cells were processed as above and total RNA was
digested with DNase I to eliminate chromosomal DNA contam-
ination (Qiagen, Valencia, CA) and purified using the Qiagen
RNeasy Mini Kit per the manufacturer’s instructions. RNA
integrity and quality was determined prior to gene expression
analysis. The manufacturer’s web-based software package was
utilized to calculate fold changes. Genes with greater than 2 fold
regulation were confirmed by qRT-PCR. The primers were
designed based on the gene identification number outlined in the
PCR array.
Statistical analysis
Statistical significance was analyzed by one-way ANOVA using
the GraphPad Software (San Diego, CA). Tukey’s test for multiple
comparisons was used for all post-analyses. Differences between
means were considered significant when *P,0.05 or better. The
data are presented as mean values 6SD.
Results
Sequential establishment of Vector, VDRff and VDRFF
constitutively expressing cell lines
The parental MCF-7 cell line is comprised of a heterogeneous
population [17] endogenously expressing the VDRFF variant [8].
To decrease endogenous VDR protein background, a cell line
expressing the lowest basal VDR protein expression was
established from parental MCF-7 cells. Single clones were isolated
as described in Materials and Methods. Figure 1A illustrates
various basal VDR protein levels. Clone 2, which expressed the
lowest basal VDR protein, was selected to generate Vector control
or cell lines overexpressing VDRff and VDRFF variants.
Figures 1B &1C depict VDRff and VDRFF pooled colonies (B)
as well as individual clones (C). The expression of VDRff and
VDRFF in MDA-MB231 pooled clones is illustrated in Figure 1D.
Figure 1. Generation of stably transfected MCF-7 cell lines with Vector, VDRff and VDRFF genotypes. (A) Single clones were isolated
from parental MCF-7 cell lines by serial dilutions in 96 well plates and clonal proteins were analyzed for basal VDR levels by immunoblotting as
described in Materials and Methods. (B) MCF-7 parental clone expressing the lowest VDR protein basal level (clone 2 from Fig. 1A) was selected for
stable transfection with the indicated plasmids and pooled protein samples were analyzed for VDR protein expression. (C and D) Single clones were
selected from stably transfected MCF-7 cells (C) and pooled MDA-MB231 clones (D) were processed for VDR protein expression by immunoblotting.
(E) MCF-7 Vector, MCF-7 VDRff and VDRFF single clones were visualized at the same passage by phase contrast microscopy at 406magnification.
doi:10.1371/journal.pone.0016024.g001
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protein was approximately 0.4 kDa shorter than the cells
overexpressing VDRff. This is consistent with the size of the
VDR variant, which is shorter by three amino acids. As shown in
Figure 1E all the three MCF-7 cell lines were morphologically
similar regardless of the VDR genotype, suggesting that the VDR
FokI polymorphism does not affect cellular phenotypes.
Differential inhibition of cell growth in VDRff and VDRFF
cells in response to 1,25D3
To compare the effect of vitamin D treatment on the
proliferation of MCF-7 cells expressing Vector, VDRff and
VDRFF, the cells were incubated in the absence or presence of
1,25D3 and counted on days 0, 3, 5 and 7 of treatment. As shown
in Figure 2A, a maximum growth inhibition of 60% (P,0.01) in
response to 1,25D3 on day 7 was observed in VDRFF cells
compared to 23% (P,0.05) and 28% (P,0.05) growth inhibition
for the Vector and VDRff cells respectively. To confirm that the
effects observed for these cell lines were consistent with each
selected VDR genotype, two additional single clones along with
the initially characterized clone, were treated with 1,25D3 for 7
days and subjected to the crystal violet assay. Similar growth
inhibition patterns were observed for all three independent clones.
The results shown in Fig. 2B are representative of three individual
clones. The differences in growth inhibition between VDRFF and
VDRff were statistically significant (P,0.01). It is important to
note that although VDRff and Vector cells were less responsive to
1,25D3, their cell growth was significantly inhibited (Vector
control vs. treatment, P,0.01, VDRff control vs. treatment;
P,0.05). Furthermore, to discern the effect of 1,25D3 on VDR
protein expression during maximum growth inhibition, the three
cell lines were treated with 100 nM 1,25D3 for 7 days and
subjected to western blotting. As illustrated in Figure 2C, VDR
protein levels were constantly upregulated in all the cell lines.
VDR induction in response to 1,25D3 was highest in VDRFF cells
followed by VDRff cells with the Vector containing the lowest
level of induction as expected. Thus, these observations indicate
that VDR plays an essential role in 1,25D3 mediated growth
inhibition. Collectively, these results imply that VDRFF cells are
more sensitive to vitamin D treatment compared to VDRff cells
and provide a platform for further examining the functional
significance of the FokI VDR polymorphism in human breast
cancer.
1,25D3 differentially regulates CYP24A1 and has no effect
on CYP27B1 transcription in FokI-VDR polymorphic cells
The results regarding the differential growth inhibitory response
of 1,25D3 on cell proliferation in the VDRff and VDRFF cell lines
prompted the investigation of whether CYP24A1, a direct Vitamin
D target gene and catabolizing enzyme [1], was also differentially
regulated in these cell lines. The expression levels of CYP24A1
mRNA and protein were compared in the three cell lines after
1,25D3 treatment. As demonstrated in Figure 3A, CYP24A1
mRNA was induced at a 1.8 fold higher rate in VDRFF expressing
cells than in VDRff cells 24 hours post 1,25D3 treatment
(P,0.05). Similarly, CYP24 mRNA levels in VDRFF cells were
Figure 2. Differential inhibition of cell growth in VDRff and VDRFF cells in response to 1,25D3. (A) The cells were grown in triplicates and
treated with 100 nM of 1,25D3 for 0-7 days and subjected to cell counting on days 0, 3, 5 and 7. (B) The cells were treated with 100 nM of 1,25D3 for 7
days and cell proliferation was determined by the crystal violet assay. The data represent analysis of three independent clones with duplicate analyses
of each clone. Bars, mean 6SD; *P,0.05, **P,0.01, ***P,0.001 (one-way ANOVA test). (C) The VDR expression was determined by western blot
analysis in the cells after incubating cells with 1,25D3 for 7 days. (D) Morphology of the cells 7 days post 1,25D3 treatment at 406magnification.
doi:10.1371/journal.pone.0016024.g002
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results were observed in parental MCF-7 cells transiently
overexpressing the two VDR variants at similar VDR levels (data
not shown). Consistent with the mRNA expression, CYP24
protein levels were also significantly upregulated in VDRFF cells
compared to the other two cell lines (Figure 3B). To further
establish the effect of VDRFF on CYP24 transactivation, effects of
vitamin D on the CYP24 promoter activity were evaluated by
luciferase assay. As expected, CYP24 reporter activity was
significantly higher in MCF-7-VDRFF cells compared to VDRff
overexpressing cells after incubation with 1,25D3 (P,0.001), (data
not shown). To confirm these findings, we conducted an
experiment with MDA-MB231 human breast cancer cells
transiently overexpressing the two different VDR variants under
identical conditions and found similar results (VDRff treatment vs
VDRFF treatment, P,0.01; Figure 3C). These results suggest that
although the VDR in Vector control and VDRff cells is functional,
VDRFF is more potent in mediating 1,25D3 upregulation of
CYP24.
CYP27B1 is important in the synthesis of the active form of
Vitamin D from its precursor 25(OH)D3 [18] and has been found
to be expressed in MCF-7 cells both at the mRNA and protein
levels [19]. Therefore, the effect of FokI polymorphism on
CYP27B1 mRNA expression was explored in MCF-7 cells. As
shown in Figure 3D, the FokI polymorphism did not alter
CYP27B1 mRNA expression after 1,25D3 treatment.
VDRFF is an effective suppressor of estrogen receptor
mediated signaling
It is well documented that ER positive breast cancer growth is
dependent on estrogen and that 1,25D3 down-regulates ERa
expression in MCF-7 cells [20]. To uncover the role of VDRff and
VDRFF on ERa signaling, the cells were exposed to 1,25D3 for
forty eight hours and ERa protein expression was assessed. As
demonstrated in Figure 4A ERa protein expression was
substantially downregulated by 62% in VDRFF cells compared
to 20% in Vector and VDRff cells after 1,25D3 treatment. The
protein band intensities were calculated after actin normalization
utilizing the UnScan-It gel program (Silk Scientific, Inc.). ERa
expression was consistently downregulated in response to 1,25D3
in parental MCF-7 cells overexpressing increasing concentrations
of VDRFF plasmid in contrast to increasing concentrations of
VDRff plasmid at equal VDR levels (data not shown), indicating
that VDRFF is more effective in mediating vitamin D action. To
further identify the effects of VDR FokI polymorphism on estrogen
mediated signaling, the cells were treated with estradiol in the
Figure 3. Effects of 1,25D3 on the expression of CYP24 and CYP27B1 in response to 1,25D3 in MCF7 cells expressing VDR
polymorphism. (A) The cells expressing Vector, VDRff or VDRFF were treated with 100 nM of 1,25D3 for 24 h; total RNA was subjected to qRT-PCR
using primers specific for the CYP24A1 gene. The data represent analyses of three independent clones. Each experimental control was set up as 1 and
each experimental treatment was normalized to its control. Bars, mean 6SD; *P,0.05, **P,0.01, ***P,0.001 (one-way ANOVA test). (B) Total cell
lysates from the same cells were processed for the indicated proteins. The data represent analyses of two independent clones (C) MDA-MB231 cells
were plated in 12 well plates in duplicates and transiently transfected with 0.3 mg of human CYP24 reporter plasmid, 0.3mg each of VDRff and VDRFF
plasmids together with 10 ng of phRL-TK internal control using Lipofectamine 2000 transfection reagent (Invitrogen). 24 h post-transfection, cells
were treated with 100 nM of 1,25D3 for 24 h. Subsequently, firefly and Renilla luciferase were determined. The normalized luciferase activity is shown.
Bars, mean 6SD; **P,0.011, ***P,0.001 (one-way ANOVA test). (D) The indicated cells were treated with 100 nM of 1,25D3 for 24 h and total RNA
was subjected to qRT-PCR using primers specific for the CYP27B1 gene. The data represent analyses of two independent clones with triplicate
analyses of each clone. Each experimental control was set up as 1 and each experimental treatment was normalized to its control.
doi:10.1371/journal.pone.0016024.g003
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induced cell growth was significantly inhibited by 1,25D3 in
VDRFF overexpressing cells (P,0. 01) while no significant
inhibition was observed in Vector and VDRff cells 4 days after
treatments. Similar results were obtained 7 days after treatments
(data not shown). Cumulatively, these results provide support for
defining the VDRff and VDRFF variants as differential mediators
of vitamin D action with the VDRFF form as the more active
modulator. Next, the effect of the anti-estrogen tamoxifen was
evaluated on estrogen stimulated cell proliferation as it is well
known to negatively arbitrate this pathway. It is well established
that tamoxifen inhibits estrogen mediated signaling by binding to
ERa and thereby preventing the activation of estrogen responsive
genes. Thus, Vector, VDRff and VDRFF cells were treated with
estradiol in the presence or absence of tamoxifen for 4 days. As
shown in Figure 4C, tamoxifen equally inhibited estrogen induced
cell growth in MCF-7-Vector, MCF-7-VDRff and MCF-7-
VDRFF cell lines (P,0.001), whereas tamoxifen as expected,
had no effect in the absence of estradiol. These results indicate that
cells with the FokI polymorphism are differentially responsive only
to vitamin D and not anti-estrogens.
VDRFF protein is more stable than VDRff protein
It is well established that 1,25D3 stabilizes VDR protein [21].
Therefore, to determine whether the difference between the two
VDR variants was due to disparities in VDR protein stability, the
cells were exposed to the protein synthesis inhibitor cycloheximide
(CHX, 10 mM) in the presence or absence of 1,25D3 for eight and
sixteen hours. As shown in Figure 5A (lanes 3 and 4), CHX
treatment inhibited the synthesis of basal VDR protein levels as
well as 1,25D3 induced VDR protein levels in VDRff cells. In
VDRFF cells however, basal VDR expression was slightly reduced
compared to control but 1,25D3 treatment rendered the receptor
resistant to CHX effects (Figure 5A, lanes 7 and 8). These
observations suggest that the VDRFF protein is more stable and
that 1,25D3 increases the half life of VDR in VDRFF cells more
effectively.
VDR FokI polymorphism has no effect on VDR and RXRa
heterodimerization
Jurutka et al identified VDRFF as possessing a stronger affinity
to bind Transcription Factor IIB, indicating one possible
mechanism for this particular variant’s enhanced transcriptional
activity [22]. To identify alternative mechanisms for the apparent
disparities in the FokI polymorphism’s sensitivity to 1,25D3,w e
compared the ability of FokI variants to heterodimerize with
RXRa, an established partner of VDR. Therefore, Vector, VDRff
and VDRFF cells were treated with 1,25D3 for twenty four hours
and subsequently subjected to co-immunoprecipitation using a
rabbit polyclonal antibody against RXRa. The immunoprecipi-
tates were subjected to western blot analysis using antibodies
directed against VDR protein (Figure 5B, left panel). Total lysates
were also analyzed for RXRa protein as a loading control
(Figure 5B right panel). As depicted in Figure 5B (left panel), the
two receptors bound together and this binding was enhanced with
1,25D3 treatment in Vector, VDRff and VDRFF cells. However,
no difference was observed in the dimerization of the VDR two
variants with RXRa. Thus, this result suggests that the differential
effects observed in these cell lines are not due to enhanced RXRa
and VDR association.
Pro-inflammatory genes and anti-apoptotic genes are
upregulated in VDRff cells
The results presented thus far characterized VDRff and
VDRFF as distinct, diversely modulating 1,25D3 action. There-
fore, a Signal Transduction Pathway Finder PCR Array (SA,
Biosciences) was employed to ascertain whether these VDR alleles
Figure 4. Effects of 1,25D3 on estrogen receptor mediated signaling in relation to selective VDR variants. (A) The cells were treated
with 100 nM of 1,25D3 for 48 h and the expressions of VDR and ERa proteins were determined. (B) The same cells were incubated with (E2) in the
presence or absence of 100 nM 1,25D3 for 4 days keeping appropriate controls and subjected to the crystal violet assay. (C) The indicated cells were
treated with E2 (10nM) in the presence or absence of 1 mM tamoxifen for 4 days and subjected to the crystal violet assay. The data represent analyses
of two independent clones with triplicate analyses of each clone. Bars, mean 6SD; **P,0.01, ***P,0.001 (one-way ANOVA test).
doi:10.1371/journal.pone.0016024.g004
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independent of 1,25D3 treatment. Table 1 shows various
differentially expressed genes with fold changes of 2.5 or higher
in VDRff cells compared to their VDRFF counterpart. Notably,
the pro-inflammatory genes Cyclooxygenase-2 (COX-2/PTGS2) [23],
Interleukin-8 (IL-8) [24] and Chemokine C-C Motif Ligand 2 (CCL2/
MCP-1) [25] were upregulated 14, 52, and 5 fold respectively in
VDRff cells compared to VDRFF cells. Additionally, the apoptosis
suppressor Baculoviral IAP repeat containing 3 (BIRC-3/cIAP2) [26]
was upregulated 8 fold. The differential expression of these genes
in FF and ff variants was confirmed by qRT-PCR. As illustrated in
Figure 6A, basal upregulation of several pro-inflammatory genes
Figure 5. Effects of 1,25D3 on the stability of VDR protein in MCF-7-VDR FokI polymorphic cells. (A) The cells were treated with 10 mM
cycloheximide in the presence or absence of 1,25D3 as described in Methods and the protein lysates were processed for VDR using western blot
analysis. (B) The indicated cells were treated with 100 nM of 1,25D3 for 24 h and total lysates were subjected to co-immunoprecipitation using an
RXRa rabbit polyclonal antibody; immunoprecipitates (left panel). The total lysates were evaluated for RXRa expression (right panel).
doi:10.1371/journal.pone.0016024.g005
Table 1. A comparison of differentially regulated genes in VDRff and VDRFF cells.
Gene ID Gene Symbol Gene Name Fold Regulation (VDRff/VDRFF) Biological Function
NM_000963 PTGS2 (COX-2) Prostaglandin-endoperoxide
synthase 2
+14.12 Pro-inflammatory, breast cancer
metastasis[23]
NM_000584 IL8 Interleukin 8 +52.71 Pro-inflammatory, breast cancer
metastasis [24]
NM_002982 CCL2 Chemokine (C-C motif) ligand 2 +5.35 Pro-inflammatory, breast cancer
metastasis [25]
NM_001165 BIRC3(cIAP) Baculoviral IAP repeat containing 3 +8.69 Apoptosis suppressor [26]
NM_005522 HOXA1 Homobox A1 +5.35 Sequence specific transcription factor,
apoptosis inhibitor in breast cancer [34]
NM_000594 TNF Tumor necrosis factor(TNF
superfamily member 2)
25.21 Cytokine, induces cell death or under
certain conditions, induces cell
proliferation and differentiation [35-36]
NM_000586 IL2 Interleukin 2 23.94 Produced by T cells, crucial for the
regulation of the immune response [37]
NM_014207 CD5 CD5 molecule 22.79 Repressor of T-cell and B-cell receptor
signaling [38]
NM_003998 NFKB1 Nuclear factor of kappa light +2.5 Transcription factor, pro-inflammatory [39]
doi:10.1371/journal.pone.0016024.t001
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16024Figure 6. Comparative expression of pro-inflammatory genes in VDRff and VDRFF cells. (A) Total RNA was isolated from the cells and
cDNA was subjected to qRT-PCR using primers specific to the indicated genes. The data represent analyses of three independent experiments. Bars,
mean 6SD; **P,0.01, ***P,0.001 (one-way ANOVA test). (B) The cells were treated with 100 nM of 1,25D3 for 24 h and total RNA was evaluated for
the expression of selected genes using qRT-PCR. The data represent analyses of three independent experiments. Bars, mean 6SD; *P,0.05, **P,0.01,
***P,0.001(one-way ANOVA test).
doi:10.1371/journal.pone.0016024.g006
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These genes include COX-2 (P,0.001), IL-8 (P,0.001), CCL2
(P,0.001) and BIRC-3 (P,0.001). The effect of 1,25D3 on the
COX-2, IL-8, CCL2 and BIRC-3 genes was also assessed in the
three cell lines. As illustrated in Figure 6B, 1,25D3 treatment of
VDRFF cells significantly downregulated the expression of IL-8
(P,0.001, VDRFF control vs. treatment), CCL2 (P,0.001,
VDRFF control vs. treatment) and BIRC-3(P,0.001, VDRFF
control vs. treatment). In VDRff cells, only CCL2 (P,0.01) and
BIRC-3(P,0.05) were downregulated in response to 1,25D3
treatment. Unexpectedly, however, COX-2 mRNA was not
significantly downregulated in VDRFF cells in response to 1,25D3.
Discussion
This study is the first report providing evidence for distinct
functional differences between VDRff and VDRFF FokI genetic
variants in MCF-7 breast cancer cells. Here we observed that
although VDRff and VDRFF overexpressing cells are morpholog-
ically similar, the VDRFF variant is more efficient in mediating
1,25D3 action. We previously reported that 1a (OH)D5,al e s s
calcemic analog of 1,25D3, inhibited the proliferation of BT474 and
ZR-75-1 breast cancer cells by 50% and 30% respectively after
72 hours of treatment [27]. Interestingly, BT474 cells are homozy-
gous for the FF allele while ZR-75-1 cells are homozygous for the ff
allele [8]. Thus, such disparities in sensitivity to vitamin D may be
attributed to polymorphisms in the VDR gene. Consequently, it is
highly plausible that a more effective transcription factor such as
VDRFF positively influences vitamin D action in vitro and in vivo.
The regulation of CYP24 by vitamin D is well characterized.
Previously it has been reported that CYP24A1 mRNA was
upregulated 7000 fold in the presence of 1,25D3 in several melanoma
cell lines, concomitant with significant growth inhibition [28]. In
contrast, CYP24A1 m R N Ai n d u c t i o nw a s1 0 0t i m e sl e s si no t h e r
melanoma cells impervious to 1,25D3 antiproliferative effects [28].
Consistent with this finding, we observed, in response to 1,25D3,t h a t
CYP24 mRNA and protein were significantly induced at a higher
rate in MCF-7-VDRFF cells compared to MCF-7-VDRff cells,
further strengthening the conclusion that the VDRFF variant
instigates a more intense response to vitamin D than its VDRff
counterpart.Interestingly,despitetheeffectsofVDRFFonCYP24A1,
no regulation was observed in CYP27B1 mRNA in any of the three
cell lines after exposure to 1,25D3. In line with this, it has been
reported that 1,25D3 has no effect on CYP27B1 activity in parental
MCF-7 cells possibly as a result of selective promoter usage [18].
Previous studies have shown that vitamin D analogs and parent
agents suppress the cell proliferation of ER+ cells more effectively
compared to ER- cells. Vitamin D analogs do not provide any
significant cell inhibitory activity in MDA-MB-231 cells, whereas
these vitamin D analogs are antiproliferative in ER+ cells [16]. The
resultspresentedinthisreportindicatethatVDRFFmayfacilitatethe
antiproliferative effects on estrogen mediated cell growth in part by
down-regulating ERa expression as it was significantly reduced in
these cells compared to the other two cell lines after 1,25D3
treatment. Together these observations demonstrate that the VDRFF
variant is an effective negative modulator of 1,25D3 on estrogen
receptor mediated signaling and that breast cancer patients whose
cells express the FF genotype may benefit from vitamin D therapy.
Another possible mechanism by which VDRFF enhances
vitamin D efficacy may be through increased receptor protein
stability. Our results revealed that 1,25D3 treatment stabilized
both VDRff and VDRFF proteins. However, VDRFF cells were
resistant to the effects of the protein synthesis inhibitor
cycloheximide even without 1,25D3 treatment, indicating that
the VDRFF protein may be more stable than VDRff protein. It
has been reported that the N terminal sequence of a protein is
often determinant of its stability [29], thus, it is possible that the
differential stability of VDRff and VDRFF may be due to a
difference in their N terminal sequence [22]. Collectively, our
results suggest that both protein stability and higher activity of the
VDRFF variant contribute to this variant’s enhanced response to
vitamin D in breast cancer cells.
One major change observed was that the basal expression of
pro-inflammatory genes COX-2, IL-8, CCL2 and BIRC-3 was
significantly upregulated in cells constitutively overexpressing the
VDRff variant. Notably, the expression of IL-8, CCL2 and BIRC-3
was downregulated by 1,25D3 treatment significantly in VDRFF
cells compared to Vector control and VDRff cells. Recent
accumulating evidence describes COX-2 as a candidate breast
cancer metastases gene [23,30–32]. For example, it has been
shown that COX-2 is one of the genes involved in potentiating
breast cancer metastasis to the brain and lung respectively [31,32].
Notably, elevated COX-2 and IL-8 expression in breast cancer
patients has been positively linked with an unfavorable prognosis
and accelerated progression to metastatic disease [30]. COX-2
overexpression in MDA-MB231 breast cancer cells and MCF10A
breast epithelial cells has also been correlated with increased IL-8
expression and COX-2 antagonists such as NS-398 have been
shown to down-regulate IL-8 [30]. Therefore, it can be inferred
that COX-2 and IL-8 may cooperate in promoting the invasion of
breast cancer cells with a VDRff genotype to other organs.
Similarly, consistent with our results, CCL2 has also recently been
reported to instigate breast cancer metastasis to the lung and bone
[25]. Together, these observations suggest that increased expres-
sion of pro-inflammatory genes such as COX2, IL-8 and CCL2 may
characterize the VDRff variant in breast cancer cells as a possible
clinical marker for aggressive tumors. It is important to note that
VDRff itself does not cause the aggressive phenotype, but due to
its increased transcriptional activity of genes implicated in an
aggressive phenotype, the VDRff genotype may fail to protect
normal cells from oncogenic insults over time.
As described in the Results, we observed upregulation of BIRC-
3 mRNA in VDRff cells indicating that breast cancer cells
expressing this genotype may be resistant to apoptosis, potentially
contributing to an unfavorable prognosis. In support of this,
knockdown of XIAP, a related member of the BIRC-3 anti-
apoptotic family in MCF-7 breast cancer cells sensitized these cells
to apoptosis mediated by chemotherapeutic drugs [33]. The
disparate expression of pro-metastasis and anti-apoptotic genes in
these cell lines may be due to the differential regulation of the
promoters of these genes by VDRff and VDRFF.
Although numerous epidemiological investigations on VDR FokI
polymorphism have painted a contradictory picture, a recent meta-
analysis of twenty one case-control studies significantly correlating
the VDRff variant with an overall enhanced breast cancer risk [13],
substantiates the experimental findings presented in this report.
Thus, a VDRff genotype may be classified as one of numerous
determinants underlying a genetic susceptibilityto a virulent form of
breastcancer,whereascellsexpressing VDRFFmaybebettersuited
for vitamin D treatment. Therefore, these observations provide an
additional genetic marker that may be clinically useful in
deciphering an individual’s response to vitamin D treatments.
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